To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
United States119th CongressHR-1492House of Representatives
Updated: Feb 21, 2025
Summary
This bill proposes to amend Title XI of the Social Security Act, specifically targeting the Drug Price Negotiation Program . Its primary goal is to equalize the negotiation period for small-molecule drugs with that of biologic candidates. Currently, small-molecule drugs are subject to price negotiation after 7 years, while biologics have an 11-year period. This legislation would change the negotiation period for small-molecule drugs from 7 years to 11 years , aligning it with the timeline for biologics. The amendment would take effect as if it had been included in the original enactment of Public Law 117-169, ensuring retroactive application.
Bill texts
All available records shown.
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
House of Representatives
All available records shown.